Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase III studies.Objective Assess the impact of BKZ...
Salvato in:
| Autori principali: | , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2025-11-01
|
| Serie: | RMD Open |
| Accesso online: | https://rmdopen.bmj.com/content/11/4/e005969.full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|